Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Accumulated Expenses: 2014-2024

Historic Accumulated Expenses for KalVista Pharmaceuticals (KALV) over the last 8 years, with Apr 2024 value amounting to $12.4 million.

  • KalVista Pharmaceuticals' Accumulated Expenses was N/A to $18.9 million in Q4 2024 from the same period last year, while for Dec 2024 it was $18.9 million, marking a year-over-year change of. This contributed to the annual value of $12.4 million for FY2024, which is N/A change from last year.
  • KalVista Pharmaceuticals' Accumulated Expenses amounted to $12.4 million in FY2024, which was up 127.28% from $5.5 million recorded in FY2020.
  • KalVista Pharmaceuticals' Accumulated Expenses' 5-year high stood at $12.4 million during FY2024, with a 5-year trough of $5.5 million in FY2020.
  • For the 1-year period, KalVista Pharmaceuticals' Accumulated Expenses averaged around $12.4 million, with its median value being $12.4 million (2024).
  • Data for KalVista Pharmaceuticals' Accumulated Expenses shows a maximum YoY declined of 3.40% (in 2020) over the last 5 years.
  • KalVista Pharmaceuticals' Accumulated Expenses (Yearly) stood at $5.5 million in 2020, then followed by $12.4 million in 2024.